ArticleScientific reports2025
MiR-340-5p regulates PD-L1 and predicts pembrolizumab response in extranodal NK/T-cell lymphoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Human biomarker navigator.iMeta · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Extranodal NK/T-cell lymphoma (ENKTL) is an aggressive, chemoresistant non-Hodgkin lymphoma subtype with poor patient outcomes linked to elevated PD-L1 expression. This study investigates miRNA-mediated regulation of PD-L1, focusing on miR-340-5p and miR-424-5p as novel therapeutic targets and predictive biomarkers for pembrolizumab response. Through miRNA sequencing and functional assays, miR-340-5p and miR-424-5p were identified as key modulators of PD-L1 in drug-resistant ENKTL cells, with their roles validated via ribonucleoprotein immunoprecipitation and luciferase reporter assays. Notably, elevated miR-340-5p levels in PD-L1-negative ENKTL tissues were inversely correlated with soluble PD-L1, implicating miR-340-5p in immune evasion mechanisms. Additionally, low serum levels of miR-340-5p were associated with reduced pembrolizumab efficacy, positioning miR-340-5p as a promising predictive biomarker for immune checkpoint blockade. These findings suggest that pre-treatment assessment of serum miR-340-5p could guide pembrolizumab therapy in ENKTL, optimizing treatment outcomes. Validation in larger cohorts is necessary to confirm the utility of miR-340-5p as a predictive biomarker for ENKTL immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.